Cingulate CING
NASDAQ CING
$4.57 +0.12 (+2.70%)
As of: Nov 10, 2026 · 12:27 PM EST

Cingulate (CING) Receivables - Net (2023 - 2024)

Updated

Analysis

Cingulate (CING) Receivables - Net (2023 - 2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 Cingulate 63.03 Mn -8.35 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 2,247.00
Jun 30, 2024 1.62 Mn
Dec 31, 2023 14,622.00
API Access

Cingulate Receivables - Net API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-net&ticker=CING&period=max&api_key=YOUR_API_KEY